News

Nanochon Wins BioHealth Capital Region 6th Annual Crab Trap Competition

Nanochon, a Washington, D.C. based company in the BioHealth Capital Region, applying novel materials to replicate bone and cartilage, and high-end 3-D printing to create an implant which can permanently repair debilitating joint injuries, was selected from five finalists as the company with the most commercial potential at the 6th Annual Crab Trap Competition. This year’s judges included industry leaders Sally Allain, Head, Johnson & Johnson Innovation – JLABS @ Washington, DC, Andrea Alms, Co-Fund Manager, BioHealth Capital Fund, Lora Green, Of Counsel, Wilson Sonsini, Goodrich & Rosati, Troy LeMaile-Stovall, Chief Executive Officer, TEDCO, Conley Jones, Senior Associate, Alexandria Venture Investments, John Newby, Chief Executive Officer, Virginia Biotechnology Association, and was moderated by Rich Bendis, President & CEO, BioHealth Innovation, Inc.

The Crab Trap, presented virtually for the second year in the row due to the pandemic, was held on September 29th in association with the 7th Annual BioHealth Capital Region and 4th Annual BioHealth Capital Region Investment Conference. Nanochon CEO, Benjamin Holmes, presented on his company’s implant, which acts as both cartilage replacement and tissue growth scaffold, and is designed to be custom 3-D printed for each patient. Nanochon joins previous Crab Trap winners, BrainScope (2020), Floreo (2019), Galen Robotics (2018), LifeSprout (2017) and Sonavex (2016).

“It is a true honor to win the BioHealth Capital Region Crab Trap this year. Being an entrepreneur, especially in life sciences, is a difficult journey. Being recognized by this panel of judges is an achievement we are proud of.” said Benjamin Holmes, Nanchon CEO. “When we first created Nanochon, we were not sure we would stay in the region long term. However, the area continues to grow and provide the support and ecosystem we need to succeed and grow too.”

In addition to Nanochone, the judges and virtual audience viewed four other finalists’ presentations: Hubly SurgicalLinshomRevalo, and VNTC.

“The companies who present as part of the Crab Trap every year continue to be remarkable with their visions for the future of BioHealth.” said Richard Bendis, BHI President & CEO. “Not only do we applaud Nanochon and all the finalists this year, but also all the competitors over the past six years of this event. They truly are the future of this industry.”

Click here for a replay of the 6th Annual Crab Trap Competition is available online by

Founded in 2016, the Crab Trap Competition focuses on companies in therapeutics, diagnostics, medical devices, healthcare services, e-health, mobile health, electronic medical records, health informatics, and biohealth cyber security.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,